Introduction {#s1}
============

Coronary heart disease (CHD) is the leading cause of mortality in African-American men and women [@pgen.1001300-NHLBI1]. The risk factors for CHD in African Americans are similar to those reported in Caucasians, but their relative impact varies between the two ethnic groups. Multiple studies have reported that smoking, type-2 diabetes (T2D), hypertension, and LDL- and HDL-cholesterol (LDL-C and HDL-C) are significant independent risk factors for CHD in African Americans [@pgen.1001300-Thomas1]--[@pgen.1001300-Cooper2]. In general, hypertension and LDL-C have a larger and smaller impact on CHD risk, respectively, in African Americans compared with Caucasians [@pgen.1001300-Jones1]. There is also extensive evidence of the role of genetic factors in the familial aggregation of CHD and its predictors in African Americans [@pgen.1001300-Katzmarzyk1]. However, the underlying genes remain largely unknown.

Recent advances in genome-wide association studies (GWAS) have made spectacular advances in identifying genes contributing to numerous common chronic diseases in Europeans and European Americans [@pgen.1001300-WTCCC1]. There are multiple loci convincingly associated with CHD risk in Caucasians, including many genes involved in lipid metabolism, as well as novel chromosomal regions that do not appear to contribute to risk through traditional risk factors [@pgen.1001300-WTCCC1]--[@pgen.1001300-Gudbjartsson1]. However, there have been no large-scale GWAS for CHD and its risk factors in African Americans. GWAS in African Americans is important because new genes may be identified as a result of genetic variation private to populations of African-descent, differences in allele frequencies and in patterns of linkage disequilibrium (LD), differences in the relative impact of risk factors to disease, or differences in gene-environment interactions. Here we report a large (and for most phenotypes first) GWAS for CHD, type-2 diabetes (T2D), hypertension, LDL-C and HDL-C, and smoking in 8,090 African Americans as part of the National Heart, Lung, and Blood Institute (NHLBI)-sponsored [C]{.ul}andidate gene [A]{.ul}ssociation [Re]{.ul}source (CARe) Project [@pgen.1001300-Musunuru1].

Results {#s2}
=======

We genotyped 909,622 single nucleotide polymorphisms in 9,119 African Americans from the ARIC (N = 3,269), CARDIA (N = 1,209), CFS (N = 704), JHS (N = 2,200), and MESA (N = 1,737) population-based cohorts, on the Affymetrix Genome-Wide Human SNP Array 6.0 platform. Genotypes were called using Birdseed v1.33 [@pgen.1001300-Korn1], and stringent quality-control filters were applied ([Tables S1](#pgen.1001300.s007){ref-type="supplementary-material"} and [S2](#pgen.1001300.s008){ref-type="supplementary-material"}). For samples that passed quality control (N = 8,100), principal component analysis (PCA) using EIGENSTRAT [@pgen.1001300-Price1] revealed only ten population outliers across all cohorts; these samples were also excluded from the analysis ([Text S1](#pgen.1001300.s019){ref-type="supplementary-material"} and [Figure S1](#pgen.1001300.s001){ref-type="supplementary-material"}). Overall, a total of 8,090 African Americans with very high genotype quality (average genotype success rate of 99.65%) were available for analysis. The demographics of these participants by cohort are shown in [Table 1](#pgen-1001300-t001){ref-type="table"}. To increase our coverage of common genetic variation and statistical power, and to facilitate comparisons across genotyping platforms, we imputed genotypes in the CARe African-American populations using MACH taking into account the admixed nature of the population ([Text S1](#pgen.1001300.s019){ref-type="supplementary-material"}) [@pgen.1001300-Li1], [@pgen.1001300-Kang1].

10.1371/journal.pgen.1001300.t001

###### Demographics of the CARe and replication African-American cohorts.

![](pgen.1001300.t001){#pgen-1001300-t001-1}

  Phenotypes[1](#nt101){ref-type="table-fn"}          ARIC               CARDIA              CFS                JHS                MESA           MEC-T2D    Cleveland Clinic   PennCATH       NHANESIII         Jamaica SPT        Jamaica GXE         Health ABC
  -------------------------------------------- ------------------- ------------------ ----------------- ------------------- ------------------- ----------- ------------------ ----------- ------------------ ------------------ ------------------ -------------------
  Gender                                            1045/1785           366/583            213/308           842/1302             745/901        835/1349        345/374         280/222        718/1002           674/1055           232/736             468/651
  Age                                               53.3±5.8            24.4±3.8          45.7±16.2          50.0±12.2           62.2±10.1       60.4±8.5       60.0±11.1       58.0±10.6      40.8±16.7          46.1±13.9           39.7±8.3           73.4±2.9
  Coronary heart disease                            110/2580               NA              25/475            125/1998               NA              NA           220/400         157/334           NA                 NA                 NA               244/895
  Type-2 diabetes                                   529/2150               NA              98/403            339/1777            298/1348        1070/1114          NA             NA           168/899               NA                 NA               335/757
  Hypertension                                      1612/1132            36/913            209/260           1193/918            1019/625           NA              NA             NA           501/1219              NA                 NA               871/263
  LDL-C                                         138.7±43.3 (2588)   111.3±31.0 (940)   99.0±33.9 (295)   125.2±36.6 (2111)   116.5±33.4 (1631)      NA              NA             NA       121.1±40.4 (805)   123.5±39.1 (928)   136.6±38.5 (928)   123.9±36.7 (1128)
  HDL-C                                         54.7±17.5 (2613)    54.4±13.0 (940)    46.4±15.0 (483)   50.0±14.1 (2138)    52.5±15.3 (1639)       NA              NA             NA       54.1±17.2 (805)    48.4±12.6 (1413)   51.5±11.5 (967)    57.1±17.6 (1138)
  Smoking                                        14.2±9.4 (799)      10.8±7.6 (359)    10.8±6.7 (178)     15.1±11.6 (659)     14.6±18.6 (873)       NA              NA             NA              NA                 NA                 NA                 NA

For gender, we reporter the number of males/females. For age, we report the mean ± standard deviation in years. For coronary heart disease, type-2 diabetes, and hypertension, we report the number of cases/controls. For LDL-C and HDL-C, we report the mean ± standard deviation in mg/dl (number of samples with phenotypes available). For smoking, we report the mean ± standard deviation in daily cigarettes, excluding non-smokers (number of samples with phenotypes available). The number of CHD cases with concomitant type-2 diabetes in the CARe cohorts is: 44 for ARIC, 14 for CFS, and 43 for JHS. NA; not available or not analyzed in this study.

For all cohorts except CFS, single marker genetic association tests were performed by study using PLINK v1.06 [@pgen.1001300-Purcell1] under an additive genetic model. We used linear regression for quantitative traits (HDL-C, LDL-C, and smoking) and logistic regression for dichotomous phenotypes (CHD, hypertension, and T2D). For CFS, family structure was modeled using linear mixed effects (LME) models and generalized estimating equations (GEE) for quantitative and dichotomous phenotypes, respectively [@pgen.1001300-Chen1]. For all analyses, the first ten principal components were used as covariates to account for global admixture and population stratification. A detailed description of the analysis methods and the phenotypic definitions used can be found in [Text S1](#pgen.1001300.s019){ref-type="supplementary-material"}. Power calculations for the different phenotypes analyzed are summarized in [Table S3](#pgen.1001300.s009){ref-type="supplementary-material"}; we have excellent power to find strong signals, but low to modest power for variants with weak phenotypic effects. The inflation factors (λ~s~) observed were all near unity ([Table S4](#pgen.1001300.s010){ref-type="supplementary-material"}), suggesting that most confounders, including population stratification, were well-controlled.

We applied genomic control to the individual cohorts\' results and combined them using the inverse variance meta-analysis method [@pgen.1001300-Willer2]. Inflation factors of the meta-analysis results were modest and were again scaled using genomic control ([Table S4](#pgen.1001300.s010){ref-type="supplementary-material"}). Quantile-quantile (QQ) plots of the six different meta-analyses after double genomic control corrections show that the test statistics follow the null expectations, except for the HDL-C and LDL-C meta-analyses, which show an upward departure from the null distributions at the lowest P-values ([Figure 1](#pgen-1001300-g001){ref-type="fig"}). This departure is caused by known genetic variants with large effects on lipid levels ([Figure S2](#pgen.1001300.s002){ref-type="supplementary-material"}).

![Quantile-quantile (QQ) plots of the meta-analyses for coronary heart disease, HDL-C, hypertension, LDL-C, smoking, and type-2 diabetes analyzed in the CARe African-American samples (N = 8,090).\
Each black circle represents an observed statistic for all genotypes and imputed SNPs (defined as the −log~10~(P-value)) against the corresponding expected statistic. The grey area corresponds to the 90% confidence intervals calculated empirically using permutations. The meta-analysis inflation factors are: coronary heart disease (λ~s~ = 0.991), HDL-C (λ~s~ = 1.030), hypertension (λ~s~ = 1.024), LDL-C (λ~s~ = 1.023), smoking (λ~s~ = 1.008), and type-2 diabetes (λ~s~ = 1.017). Data shown are genomic controlled before (for each study) and after the meta-analysis.](pgen.1001300.g001){#pgen-1001300-g001}

The main goal of this study was to identify new genetic risk factors for CHD and its predictors in African Americans. For five traits analyzed (we could not identify African-American replication cohorts for smoking), we identified SNPs with the strongest evidence of association in the CARe meta-analysis -- SNPs were selected after accounting for LD to limit association signals redundancy -- and sought replication using *in silico* data or direct genotyping in independent African-American cohorts ([Table 1](#pgen-1001300-t001){ref-type="table"}).

Combined results from a meta-analysis of the CARe and replication data are presented in [Tables S5](#pgen.1001300.s011){ref-type="supplementary-material"}, [S6](#pgen.1001300.s012){ref-type="supplementary-material"}, [S7](#pgen.1001300.s013){ref-type="supplementary-material"}, [S8](#pgen.1001300.s014){ref-type="supplementary-material"}, [S9](#pgen.1001300.s015){ref-type="supplementary-material"} and summarized in [Table 2](#pgen-1001300-t002){ref-type="table"}. We identified one novel locus that reached the generally accepted level for genome-wide significance (*P*≤5×10^−8^): SNP rs7801190 in the potassium/chloride transporter gene *SLC12A9* and hypertension (OR = 1.31, combined *P* = 3.4×10^−8^). Despite reaching genome-wide significance, we are cautious in highlighting this association because it was identified using imputed genotypes (imputation quality r^2^\_hat = 0.70) and the replication result, also obtained by imputation, was not statistically significant (*P* = 0.29). Indeed, when we directly assessed the quality of the imputation by directly genotyping rs7801190 in ARIC African-American samples (N = 2,572), we failed to validate the observed association with hypertension. This result suggests that the association between rs7801190 and hypertension status observed in the CARe African-American datasets is likely due to chance.

10.1371/journal.pgen.1001300.t002

###### Novel genetic associations (*P*≤1×10^−6^) between SNPs and coronary heart disease or its risk factors in African Americans.

![](pgen.1001300.t002){#pgen-1001300-t002-2}

  Trait              SNP       CHR (POS)[1](#nt102){ref-type="table-fn"}   Reference allele (reference allele frequency)[2](#nt103){ref-type="table-fn"}   CARe meta-analysis    Replication        Combined         Locus                                      
  -------------- ------------ ------------------------------------------- ------------------------------------------------------------------------------- --------------------- ------------- --------------------- -------- --------------------- ------------ -----------
  HDL-C           rs7323893                  13 (87502707)                                                   T (0.91)                                        −0.138 (0.030)      5.7×10^−6^      −0.131 (0.047)      0.0053     −0.136 (0.025)      1.3×10^−7^  
                   rs937254                  15 (55697456)                                                   A (0.57)                                         0.077 (0.017)      5.4×10^−6^       0.078 (0.043)      0.067       0.077 (0.016)      1.0×10^−6^    *GCOM1*
  Hypertension    rs7801190                  7 (100296029)                                                   C (0.73)                                      1.35 \[1.22--1.50\]   2.5×10^−8^    1.13 \[0.90--1.44\]    0.29    1.31 \[1.19--1.44\]   3.4×10^−8^   *SLC12A9*
  LDL-C           rs13161895                 5 (179403807)                                                   T (0.08)                                         0.151 (0.035)      2.3×10^−5^       0.139 (0.052)      0.0077      0.147 (0.029)      5.8×10^−7^   *RNF130*

Coordinates are on NCBI build 36.1.

Average frequency for the reference allele across all available African-American CARe samples.

Direction of the effect given for the reference allele; OR, odds ratio; CI, confidence interval; SE, standard error.

P-values are scaled using genomic control.

To validate our phenotype modeling and analytical strategy, we sought to replicate in the CARe meta-analyses genetic associations previously reported in populations of European ancestry. We retrieved all index SNPs associated at genome-wide significance level with CHD, T2D, hypertension, HDL-C, LDL-C, and smoking in Caucasians as well as their proxy SNPs (defined as markers with an *r^2^*≥0.5 with the index SNPs in HapMap samples of European ancestry (CEU)) ([Table S10](#pgen.1001300.s016){ref-type="supplementary-material"}) [@pgen.1001300-Hindorff1]. We then determined whether there was also evidence of association for the same signals in this large sample of African Americans. We detected modest to strong evidence of replication for one locus associated with CHD, one locus with T2D, nine with HDL-C, and six with LDL-C ([Table 3](#pgen-1001300-t003){ref-type="table"} and [Table S11](#pgen.1001300.s017){ref-type="supplementary-material"}). We did not replicate signals associated with smoking or hypertension. Furthermore, the top ten associated SNPs in a recent hypertension GWAS performed in African Americans [@pgen.1001300-Adeyemo1] were not associated with hypertension in the CARe meta-analysis (different direction of effect and/or *P*\>0.05). Since these hypertension association signals did not replicate in the original publication, non-replication here may result from their being falsely positive in the original report. Although replication of some of the above loci in African-derived populations had been reported previously [@pgen.1001300-Helgason1], for most of them, the CARe results represent the first replication in populations of African ancestry.

10.1371/journal.pgen.1001300.t003

###### Replication of associations previously reported in Caucasians in the CARe African-American meta-analyses.

![](pgen.1001300.t003){#pgen-1001300-t003-3}

  Trait                                   Locus                 Chr.    CARe SNP^a^     Position[b](#nt107){ref-type="table-fn"}   Effect allele[c](#nt108){ref-type="table-fn"}   Average effect allele frequency in CARe (SE)   Odds ratio/Beta[d](#nt109){ref-type="table-fn"}   95% CI/SE[d](#nt109){ref-type="table-fn"}   P-value[e](#nt110){ref-type="table-fn"}            Reference
  ------------------------ ----------------------------------- ------ ---------------- ------------------------------------------ ----------------------------------------------- ---------------------------------------------- ------------------------------------------------- ------------------------------------------- ----------------------------------------- -----------------------------
  Coronary heart disease           *CDKN2A*, *CDKN2B*            9       rs4977574                      22088574                                         G                                        0.177 (0.004)                                      1.18 (OR)                                   \[0.93--1.49\]                                  0.17                     [@pgen.1001300-Kathiresan1]
                                                                 9     rs6475606 (p)                    22071850                                         C                                        0.109 (0.003)                                      2.00 (OR)                                   \[1.34--2.96\]                               6.4×10^−4^                 
  Type-2 diabetes                       *TCF7L2*                 10      rs7903146                     114748339                                         T                                        0.291 (0.005)                                      1.33 (OR)                                   \[1.19--1.48\]                               3.5×10^−7^                   [@pgen.1001300-Zeggini1]
  HDL-C                                 *GALNT2*                 1       rs2144300                     228361539                                         T                                        0.143 (0.012)                                    0.092 (BETA)                                       0.029                                     0.0015                      [@pgen.1001300-Willer1]
                                        *PPP1R3B*                8       rs9987289                      9220768                                          A                                        0.191 (0.005)                                    −0.090 (BETA)                                      0.022                                   4.3×10^−5^                  [@pgen.1001300-Teslovich1]
                                          *LPL*                  8       rs10503669                     19891970                                         A                                        0.059 (0.006)                                    0.137 (BETA)                                       0.035                                   7.2×10^−5^                    [@pgen.1001300-Willer1]
                                                                       rs10096633 (p)                   19875201                                         T                                        0.430 (0.039)                                    0.101 (BETA)                                       0.017                                   1.5×10^−9^                 
                                         *ABCA1*                 9       rs3905000                     106696891                                         A                                        0.161 (0.011)                                    −0.043 (BETA)                                      0.022                                      0.054                    [@pgen.1001300-Aulchenko1]
                                                                       rs13284054 (p)                  106708894                                         C                                        0.850 (0.005)                                    0.090 (BETA)                                       0.027                                     0.0011                   
                                  *FADS1, FADS2, FADS3*          11       rs174547                      61327359                                         C                                        0.092 (0.009)                                    −0.055 (BETA)                                      0.030                                      0.068                    [@pgen.1001300-Kathiresan2]
                                                                 11      rs1535 (p)                     61354548                                         A                                        0.820 (0.009)                                    −0.102 (BETA)                                      0.025                                   6.7×10^−5^                 
                                         *LIPC*                  15      rs1800588                      56510967                                         T                                        0.497 (0.017)                                    0.102 (BETA)                                       0.018                                   1.5×10^−8^                  [@pgen.1001300-Kathiresan3]
                                                                       rs8034802 (p)                    56512084                                         A                                        0.362 (0.010)                                    0.104 (BETA)                                       0.017                                   1.3×10^−9^                 
                                         *CETP*                  16      rs3764261                      55550825                                         A                                        0.305 (0.010)                                    0.203 (BETA)                                       0.023                                   8.6×10^−18^                   [@pgen.1001300-Willer1]
                                                                        rs247617 (n)                    55548217                                         A                                        0.258 (0.006)                                    0.260 (BETA)                                       0.019                                   1.2×10^−43^                
                                         *LCAT*                  16       rs255052                      66582496                                         A                                        0.218 (0.009)                                    0.132 (BETA)                                       0.020                                   6.6×10^−11^                   [@pgen.1001300-Willer1]
                                         *PLTP*                  20        rs7679                       44009909                                         T                                        0.958 (0.005)                                    0.052 (BETA)                                       0.041                                      0.22                     [@pgen.1001300-Kathiresan2]
                                                                       rs6065904 (p)                    43968058                                         A                                        0.202 (0.010)                                   −0.0904 (BETA)                                      0.023                                   7.4×10^−5^                 
  LDL-C                                  *DOCK7*                 1       rs10889353                     62890784                                         A                                        0.618 (0.012)                                    0.049 (BETA)                                       0.017                                     0.0040                    [@pgen.1001300-Aulchenko1]
                                                                 1     rs10889335 (p)                   62732689                                         A                                        0.606 (0.018)                                    0.068 (BETA)                                       0.018                                   1.2×10^−4^                 
                               *CELSR2*, *PSRC1*, *SORT1*        1       rs12740374                    109619113                                         T                                        0.235 (0.003)                                    −0.174 (BETA)                                      0.021                                   1.3×10^−16^                 [@pgen.1001300-Kathiresan2]
                                         *PCSK9*                 1     rs10493178 (n)                   55369655                                         A                                        0.878 (0.007)                                    0.177 (BETA)                                       0.025                                   4.7×10^−12^                
                                         *APOB*                  2        rs562338                      21141826                                         A                                        0.598 (0.009)                                    −0.089 (BETA)                                      0.017                                   3.1×10^−7^                  [@pgen.1001300-Kathiresan3]
                                                                        rs503662 (p)                    21267647                                         T                                        0.652 (0.010)                                    −0.110 (BETA)                                      0.018                                   2.5×10^−9^                 
                                         *LDLR*                  19      rs6511720                      11063306                                         T                                        0.144 (0.002)                                    −0.208 (BETA)                                      0.038                                   7.2×10^−8^                  [@pgen.1001300-Kathiresan2]
                            *APOE*, *APOC1*, *APOC4*, *APOC2*    19    rs1160985 (n)                    50095252                                         T                                        0.635 (0.011)                                    −0.166 (BETA)                                      0.017                                   7.2×10^−21^                

To be included in this table, we require a two-tailed *P*≤0.05 after Bonferroni correction for the number of independent loci reported in the NHGRI database ([Table S5](#pgen.1001300.s011){ref-type="supplementary-material"}). We report the association results for the published (index) SNP, unless it is not available. In that case, we report results for a proxy SNP (*r*^2^≥0.5 with original SNP in HapMap CEU; see [Table S5](#pgen.1001300.s011){ref-type="supplementary-material"} for additional details).

Proxy SNPs are marked with (p). SNPs that have a strong association signal but are not in LD with the published SNP are marked with (n) as potentially novel.

Position on NCBI build 36.1.

Effect alleles are given on the forward strand. For proxy SNPs, we phased HapMap CEU genotypes for the index and proxy SNPs to determine haplotypes, to be able to assess consistency of the direction of effect.

For dichotomous phenotypes, we report odds ratio (OR) and 95% confidence interval (CI); for quantitative traits, we report effect size (beta, in standard deviation units) and standard error (SE).

P-values are corrected using genomic control.

Taking advantage of the LD patterns in African Americans (LD breakdown over shorter distances compared with Caucasians), we assessed whether we could fine-map some of the associations previously reported in Caucasians. For this, we evaluated SNPs that were correlated with the index SNP in HapMap CEU (*r^2^*≥0.5), but largely uncorrelated with it in HapMap samples of African descent (YRI)(*r^2^*≤0.1). In most cases, the same signals were responsible for the associations in Caucasians and African Americans ([Table 3](#pgen-1001300-t003){ref-type="table"} and [Table S11](#pgen.1001300.s017){ref-type="supplementary-material"}). However, we found five examples where the predominant association signals were at SNPs strongly correlated with the index SNPs in HapMap CEU but weakly or not correlated with the index SNPs in HapMap YRI: the *CDKN2A/CDKN2B* locus for CHD and the *FADS1-3*, *PLTP*, *LPL*, and *ABCA1* loci for HDL-C ([Table S12](#pgen.1001300.s018){ref-type="supplementary-material"}). Using available genetic association results for myocardial infarction [@pgen.1001300-Kathiresan1] and HDL-C [@pgen.1001300-Kathiresan2] in Caucasians, we illustrate in [Figure 2](#pgen-1001300-g002){ref-type="fig"} and [Figure S3](#pgen.1001300.s003){ref-type="supplementary-material"} how our results in African Americans can help refine association signals. For instance, for the *FADS* locus, the index SNP in Caucasians (rs174547) is in strong LD with the top SNP in the CARe African-American meta-analysis (rs1535) in HapMap CEU (*r*^2^ = 1) but not in HapMap YRI (*r*^2^ = 0.09). The region of strong LD around rs174547 in HapMap CEU is 113 kb wide and includes the three *FADS* genes, whereas rs1535, located in an intron of *FADS2*, is in strong LD with no other markers in HapMap YRI ([Figure 2](#pgen-1001300-g002){ref-type="fig"}). Comparison of association signals regionally in African Americans and European-derived individuals can thus be useful in two ways: (1) they may suggest smaller chromosomal regions for re-sequencing experiments to attempt to identify causal variant(s) that underlie shared signals between African- and European-derived chromosomes or (2) they may indicate that the index SNPs for African and European populations are linked to distinct causal variants. A third potentially interesting result from trans-ethnic comparison of association results is the identification of ethnic-specific association signals. For instance, at the *ABCA1* locus, three SNPs in LD (rs4743763, rs4149310, and rs2515629) are associated with HDL-C in CARe African Americans (*P*\<1×10^−5^), but not in Caucasians ([Figure S3D](#pgen.1001300.s003){ref-type="supplementary-material"}).

![HDL-C association results in Caucasians (top panel) [@pgen.1001300-Kathiresan2] and in the CARe African Americans (bottom panel) at the *FADS* locus.\
Plots were generated using LocusZoom [@pgen.1001300-Pruim1]. Under the top panel, the light blue box corresponds to the chromosomal interval flanked by the leftmost and rightmost SNPs with a *r*^2^≥0.3 with the index SNP rs174547 in HapMap CEU. In the bottom panel, there is no light blue box because the top CARe SNPs at this locus, rs1535, is not in strong LD with any markers in HapMap YRI.](pgen.1001300.g002){#pgen-1001300-g002}

The optimal analytical strategy for GWAS in recently admixed populations has not been established. In African Americans, an ideal test statistic would incorporate both genotype information as traditionally used in GWAS, but also, at each locus, the probability that a given individual has zero, one, or two copies of a European (or African) chromosomal segment. This method would be particularly informative in a case where, for example, the causal allele is not in LD with any markers on the genotyping array, but is at higher frequency on one ancestral background. To explore the benefits of such a statistical framework, we designed and applied a novel method that combines evidence of association from genotypes and local ancestry estimates; the method is described in details in [Text S1](#pgen.1001300.s019){ref-type="supplementary-material"}. Briefly, we use a panel of ancestry informative markers across the genome and a new implementation of the software ANCESTRYMAP [@pgen.1001300-Patterson1] to estimate, for each of the CARe African Americans genotyped, the probabilistic proportion of European ancestry (0--100%) at the locus for each of the ∼900,000 SNPs genotyped on the Affy6.0 platform. For each SNP, we can then compute association between the phenotype and both the SNP genotype and the SNP estimate of local ancestry to generate a combined score that summarizes allelic variation and admixture. This method was used to produce the association data presented in [Table 4](#pgen-1001300-t004){ref-type="table"}.

10.1371/journal.pgen.1001300.t004

###### Top novel associations (*P*≤1×10^−6^) identified using SNP genotype and estimate of local African versus European ancestry.

![](pgen.1001300.t004){#pgen-1001300-t004-4}

  TRAIT                        SNP       CHR (POS)[1](#nt113){ref-type="table-fn"}   Reference allele   Reference allele frequency   SNP-only   SNP+Estimate of local ancestry   Closest genes[7](#nt119){ref-type="table-fn"}                                              
  ------------------------ ------------ ------------------------------------------- ------------------ ---------------------------- ---------- -------------------------------- ----------------------------------------------- ------------ -------- -------- ------------ ----------------
  Coronary heart disease    rs6674681                  1 (79493711)                         T                      0.75                0.23                  0.88                               0.0892 (0.1151)                     0.44      3.524    −4.14    3.8×10^−7^  
                            rs6753112                  2 (231895399)                        T                      0.87                0.31                  0.91                              −0.2459 (0.1357)                     0.07      −3.977   3.625    5.2×10^−7^      *ARMC9*
  HDL-C                     rs8078633                   17 (559286)                         C                      0.31                1.00                  0.18                              −0.0006 (0.0186)                     0.98      −3.893   4.723    3.6×10^−7^      *APPBP2*
  Hypertension              rs10218356                 23 (19168233)                        A                      0.20                0.94                  0.04                              −0.0915 (0.0523)                     0.08      −4.056   3.891    6.5×10^−7^  
  LDL-C                     rs17441606                 2 (19431916)                         A                      0.17                0.32                  0.11                              −0.0759 (0.0219)                  6.2×10^−4^   −4.234   4.021    4.0×10^−8^       *OSR1*
                            rs9306885                  2 (19852313)                         T                      0.26                0.72                  0.16                              −0.0329 (0.0197)                     0.10      −4.144   4.321    1.7×10^−8^  
                            rs6728440                  2 (19862827)                         A                      0.96                0.87                  1.00                               0.0978 (0.0446)                     0.03      3.527    −4.029   5.9×10^−8^      *TTC32*
                            rs7560236                  2 (22930288)                         T                      0.06                 0                    0.08                               0.1493 (0.0366)                  5.5×10^−5^   4.568    3.804    2.1×10^−8^  
                            rs6748157                  2 (28586865)                         A                      0.86                0.51                  0.98                                0.03 (0.0247)                      0.23      3.592    −4.062   4.1×10^−8^       *PLB1*
  Smoking                   rs7075036                  10 (16904816)                        T                      0.69                0.32                  0.80                              −0.1326 (0.0296)                  8.4×10^−6^   −5.036   2.054    8.0×10^−7^   *RSU1*, *CUBN*
                            rs11088655                 21 (18128360)                        T                      0.41                0.22                  0.52                               0.0938 (0.0275)                  6.9×10^−4^   4.347    3.637    2.4×10^−7^     *C21orf91*
                            rs16982414                 21 (28711411)                        T                      0.90                0.99                  0.84                              −0.1646 (0.0432)                  1.5×10^−4^   −4.375   −3.327   6.0×10^−7^  

Global ancestry is included in the model for both methods.

Coordinates are on NCBI build 36.1.

Average frequency for the reference allele across all available African American CARe samples.

Direction of the effect given for the reference allele; SE, standard error.

P-values are scaled using genomic control.

Z-score for the SNP genotype information. A Z-score \>0 means that the trait (or the risk to develop the disease) increases with the number of copies of reference alleles.

Z-score for the local ancestry estimate information. A Z-score \>0 means that the trait (or the risk to develop the disease) increases with the number of copies of European chromosomes.

Genes in a 200 kb window.

Our method to assess combined SNP- and ancestry-association was tested explicitly on CHD and its risk factors in the CARe African-American samples ([Figures S4](#pgen.1001300.s004){ref-type="supplementary-material"}, [S5](#pgen.1001300.s005){ref-type="supplementary-material"}). For each SNP, we compared the test statistic obtained using the SNP-alone or the SNP+admixture information (in both methods, global ancestry is included as a covariate), focusing on markers that would not have been prioritized for follow-up replication when considering only SNP genotype association results ([Figure S6](#pgen.1001300.s006){ref-type="supplementary-material"}). Across the six phenotypes, we identified 12 SNPs outside the previously known loci with a *P*≤1×10^−6^ in this SNP+admixture test statistic ([Table 4](#pgen-1001300-t004){ref-type="table"}). Most of these SNPs have a large allele frequency difference between the HapMap CEU and YRI individuals, suggesting that local ancestry might confound simple SNP association testing. For instance, the frequency of the C-allele at rs8078633 near the *APPBP2* gene is 100% and 18% in CEU and YRI, respectively. The association between this SNP and HDL-C levels is weak when considering only allelic variation (*P* = 0.98) but becomes highly significant when evidence from the genotype and the estimate of local ancestry is combined (*P* = 3.6×10^−7^) ([Table 4](#pgen-1001300-t004){ref-type="table"}). This composite approach also identified a SNP near the phospholipase B1 gene (*PLB1*) that is strongly associated with LDL-C levels (*P* = 4.1×10^−8^), but that would not have been noticed using traditional genotype-only association testing (*P* = 0.23) ([Table 4](#pgen-1001300-t004){ref-type="table"}). As more large-scale GWAS in individuals of African ancestry are completed, it will be important to replicate these results.

Discussion {#s3}
==========

Most large-scale genetic efforts to identify risk factors for CHD have focused so far on populations of European ancestry. Given the prevalence of the disease in African Americans, and the development of better genotyping platforms that more completely survey common genetic variation in African-derived genomes [@pgen.1001300-Korn1], it is now both pertinent and timely to investigate the genetics of CHD in populations of African ancestry. The CARe Project was launched four years ago with the specific goal to create a resource for association studies of various heart-, lung-, and blood-related phenotypes across different ethnic groups [@pgen.1001300-Musunuru1]. In this article, we present results from the largest GWAS to date for CHD and its risk factors in African Americans. Despite being the largest, the size of our GWAS is modest compared to that of some European-derived consortia. As a consequence, we had limited discovery power and did not identify novel loci specifically associated with CHD or its risk factors that reach genome-wide significance in our African-American dataset.

We also attempted to replicate in the CARe African-American participants genetic associations to CHD and its risk factors previously identified in Caucasians. We could replicate 17 of those associations; for many of them, this was the first replication in a non-European-derived population ([Table 3](#pgen-1001300-t003){ref-type="table"}). For five of these 17 associations, we showed how cross-ethnic comparisons of genetic association results may help refine genomic intervals carrying causal alleles ([Figure 2](#pgen-1001300-g002){ref-type="fig"} and [Figure S3](#pgen.1001300.s003){ref-type="supplementary-material"}). There were, however, a large number of loci originally found in Caucasians that were not replicated in the CARe meta-analyses presented in this manuscript ([Table S11](#pgen.1001300.s017){ref-type="supplementary-material"}). Because our sample size was relatively modest, that we used stringent statistical thresholds to declare replication in order to control our false positive rate, and that effect sizes could be weaker for given loci across different ethnic groups, our limited power probably explains why many loci did not replicate in the CARe African Americans. Alternatively, some of these non-replications could be explained by the absence of variants within these loci associated with these traits in African Americans. Our data does not allow us to distinguish these two possibilities, and larger replication studies in African-American cohorts will be needed to draw informative conclusions.

Taken together, our results suggest that CHD risk in African Americans is not influenced by loci with major phenotypic effect on disease risk, but rather by multiple variants of weak effect, as we have observed for CHD and other traits in Caucasians. Because opportunities for replication and meta-analysis with other African-American cohorts are evolving rapidly, the CARe dataset is an outstanding public resource that provides a strong base for discovery of genetic contributors to CHD in non-European-derived populations.

Materials and Methods {#s4}
=====================

Ethics statement {#s4a}
----------------

All participants gave informed written consent. The CARe project is approved by the ethic committees of the participating studies and of the Massachusetts Institute of Technology.

Studies {#s4b}
-------

African-American participants for the GWAS were drawn from five population-based studies: Atherosclerosis Risk in Communities (ARIC; N = 3,269), Coronary Artery Risk Development in young Adults (CARDIA; N = 1,209), Cleveland Family Study (CFS; N = 704), Jackson Heart Study (JHS; N = 2,200), and Multi-Ethnic Study of Atherosclerosis (MESA; N = 1,737). Although longitudinal data is available for most participants, only information collected at recruitment was considered in this GWAS. Replication results for top SNP associations were obtained using *in silico* or *de novo* genotyping from four African-American and African-Caribbean population-based cohorts (Health, Aging, and Body Composition Study (Health ABC; N = 1,119), National Health and Nutrition Examination Survey III (NHANES III, N = 1,720), Jamaica Spanish Town (SPT, N = 1,746) and Jamaica GXE (N = 969), one nested case-control panel from the population-based Multiethnic Cohort (MEC, N = 2,184), and two case-control panels (Cleveland Clinic, N = 620, and PennCATH, N = 491). A detailed description of all cohorts and phenotype definitions used in this study is provided in [Text S1](#pgen.1001300.s019){ref-type="supplementary-material"}.

Genotyping and quality controls {#s4c}
-------------------------------

All discovery samples (GWAS) were genotyped on the Affymetrix Genome-Wide Human SNP array 6.0 according to the manufacturer\'s protocol. For replication, the MEC samples were genotyped by Taqman, and the NHANES III, Jamaica SPT, Jamaica GXE, Cleveland, and UPENN samples were genotyped using Illumina\'s Oligos Pool All (OPA) technology. The Health ABC samples were genotyped on the Illumina Human1M-Duo BeadChip array as part of an independent GWAS; SNP results for the replication of the CARe findings were extracted and analyzed. Several quality control (QC) filters were applied to the genome-wide genotype data: DNA concordance checks; sample and SNP genotyping success rate (\>95%, minor allele frequency ≥1%); sample heterozygosity rate, identity-by-descent analysis to identify population outliers ([Figure S1](#pgen.1001300.s001){ref-type="supplementary-material"}), problematic samples, and cryptic relatedness; Mendel errors rate in CFS and JHS, and SNP association with chemistry plates. For replication, SNPs and samples with genotyping success rate \<90% were excluded. Because of the admixed nature of the participants, SNPs were not removed solely because they departed from Hardy-Weinberg equilibrium. A detailed description of the quality control checks applied to the discovery (GWAS) and replication genotyping data can be found in [Text S1](#pgen.1001300.s019){ref-type="supplementary-material"}.

SNP imputation {#s4d}
--------------

To increase coverage and facilitate comparison with other datasets, we imputed genotype data using MACH v1.0.16 [@pgen.1001300-Kang1]. We built a panel of reference haplotypes using HapMap phase II CEU and YRI data, and imputed SNP genotypes using all Affymetrix 6.0 SNPs that passed the QC steps described above. Using and independent dataset of ∼12,000 SNPs genotyped on the same DNA but with a different platform, we estimated an allelic concordance rate of 95.6% ([Text S1](#pgen.1001300.s019){ref-type="supplementary-material"}).

Association analyses {#s4e}
--------------------

SNP-only based genetic association analysis of quantitative (HDL-C, LDL-C, smoking) and dichotomous (coronary heart disease, type-2 diabetes, hypertension) traits were carried out using linear and logistic statistical framework, respectively, in PLINK (unrelated cohorts: ARIC, CARDIA, JHS, MESA, UPENN, Cleveland, MEC, NHANES III, and Health ABC) or using R scripts that model family structure (related cohort: CFS) [@pgen.1001300-Chen2]. For the cohorts with genome-wide genotyping data available, the first ten principal components were included in each analysis to account for population stratification and admixture. The method to estimate local ancestry was implemented in ANCESTRYMAP and is described in details in [Text S1](#pgen.1001300.s019){ref-type="supplementary-material"}. To combine allelic and local ancestry information ([Table 4](#pgen-1001300-t004){ref-type="table"}), we calculated a chi-square statistic with two degrees-of-freedom. Association results were combined across cohorts using an inverse variance meta-analysis approach as implemented in metal.

URL {#s4f}
---

CARe: <http://www.broadinstitute.org/gen_analysis/care/index.php/Main_Page>; MACH: <http://www.sph.umich.edu/csg/abecasis/MACH>; METAL: <http://www.sph.umich.edu/csg/abecasis/Metal/index.html>; PLINK: <http://pngu.mgh.harvard.edu/~purcell/plink>.

Supporting Information {#s5}
======================

###### 

Plots of the two main principal components (PC) in the CARe African-American samples. European-Americans and Nigerians samples are used as reference populations. We note that the first principal component (PC1) captures European vs. African global ancestry. For CFS, outliers on PC2 all belong to the same large family.

(0.25 MB TIF)

###### 

Click here for additional data file.

###### 

Manhattan plots summarizing the meta-analysis results for the six phenotypes analyzed after double genomic control scaling. The dashed line highlights genome-wide significance (P-value = 5×10^−8^). The genome-wide significant loci include 8p23 (chr8), *LPL* (chr8), *LIPC* (chr15), *LCAT* (chr16), and *CETP* (chr16) for HDL-C, *SLC12A9* (chr7) for hypertension, and *PCSK9* (chr1), *CELSR2-PSRC1-SORT1* (chr1), and *APOE* (chr19) for LDL-C.

(1.27 MB TIF)
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Click here for additional data file.

###### 

Graphical representation of the information summarized in [Table S12](#pgen.1001300.s018){ref-type="supplementary-material"}. Plots were drawn using LocusZoom [@pgen.1001300-Kathiresan2]. CHD association results in Caucasians are from Kathiresan et *al.* [@pgen.1001300-Patterson1]. HDL-C association results in Caucasians are from Kathiresan et *al.* [@pgen.1001300-Chen2]. Under each plot, the light blue box corresponds to the genomic intervals flanked by the leftmost and rightmost SNPs with and *r*^2^≥0.3 with the index SNPs (purple diamond). For the results in Caucasians, we used LD based on HapMap CEU, and for the results in African Americans, LD based on HapMap YRI. For the *PLTP* and *ABCA1* loci, the CARe SNPs (respectively rs6065904 and rs13284054) define genomic intervals of 0.2 kb using the *r*^2^≥0.3 threshold, which appear as light blue lines on the plots.

(1.59 MB TIF)
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Click here for additional data file.

###### 

Quantile-quantile (QQ) plots of the meta-analyses results that take into account local ancestry estimates and SNP genotypes (Chi-square with two degrees-of-freedom (N = 8,090). Each black circle represents an observed statistic for genotyped SNPs only (defined as the −log~10~(P-value)) against the corresponding expected statistic. The grey area corresponds to the 90% confidence intervals calculated empirically using permutations. The meta-analysis inflation factors are: coronary heart disease (λ~s~ = 0.923), HDL-C (λ~s~ = 1.030), hypertension (λ~s~ = 1.121), LDL-C (λ~s~ = 1.290), smoking (λ~s~ = 1.060), and type-2 diabetes (λ~s~ = 1.109). Data shown is genomic controlled before (for each study) and after the meta-analysis.

(0.26 MB TIF)
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Click here for additional data file.

###### 

Manhattan plots summarizing the meta-analysis results that take into account local ancestry estimates and SNP genotypes (two degrees-of-freedom). Results are shown for the six phenotypes analyzed after double genomic control scaling. The dashed line highlights genome-wide significance (P-value = 5×10^−8^). The genome-wide significant loci include *LCAT* (chr16) and *CETP* (chr16) for HDL-C and *PCSK9* (chr1), *CELSR2-PSRC1-SORT1* (chr1), 2p24 (chr2), and *APOE* (chr19) for LDL-C.

(1.23 MB TIF)
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Click here for additional data file.

###### 

Comparison of P-values (-log~10~ scale) for the meta-analysis results obtained using SNP genotype-only (x-axis) or SNP genotype+estimate of local ancestry (y-axis) to compute the test statistics. Each black circle corresponds to a SNP. In total, results from ∼885,000 genotyped SNPs were available for each method. The gray line represents perfect correlation (x = y). The horizontal and vertical dashed lines represent the pre-defined threshold for genome-wide significance (P-value = 5×10^−8^).
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Click here for additional data file.
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Sample exclusion for the CARe Affy6.0 datasets.
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Click here for additional data file.
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SNP exclusion for the CARe Affy6.0 datasets.

(0.04 MB DOC)
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Click here for additional data file.

###### 

Power calculations for the different phenotypes analyzed by the CARe Project in this study. The assumptions are: an additive inheritance model, an effect allele frequency of 10%, and an alpha threshold of 1×10^−6^ (which was arbitrary selected to promote SNPs for replication). We also assume that all samples belong to a single study; in practice, there is a small loss of power because of the meta-analysis. For case-control, power calculations were done using the Genetic Power Calculator (<http://pngu.mgh.harvard.edu/~purcell/gpc/>). For quantitative traits, power calculations were done using Quanto (<http://hydra.usc.edu/gxe/>).
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Click here for additional data file.

###### 

Inflation factors (λ~s~) for the different phenotypes analyzed, by cohort and for the corresponding meta-analyses.
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Click here for additional data file.

###### 

Coronary heart disease replication results for SNPs from the CARe meta-analysis.

(0.25 MB DOC)
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Click here for additional data file.
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HDL-C replication results for SNPs from the CARe meta-analysis.

(0.21 MB DOC)
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Click here for additional data file.
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Hypertension replication results for SNPs from the CARe meta-analysis.

(0.21 MB DOC)
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Click here for additional data file.
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LDL-C replication results for SNPs from the CARe meta-analysis.

(0.22 MB DOC)
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Click here for additional data file.

###### 

Type-2 diabetes replication results for SNPs from the CARe meta-analysis.

(0.10 MB DOC)

###### 

Click here for additional data file.

###### 

Loci associated at genome-wide significance level with CHD or its risk factors in Caucasians (data retrieved from the NHGRI database; <http://www.genome.gov/26525384>).
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###### 

CARe meta-analysis association results (including data from ARIC, CARDIA, CFS, JHS, and MESA) for the SNPs associated with coronary heart disease and its risk factors in Caucasians. In yellow, we highlight the five loci where association signals in African Americans define smaller genomic intervals to search for causal allele(s).
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Linkage disequilibrium-based genomic intervals of loci previously associated with coronary heart disease and HDL-C in Caucasians using the CARe datasets.
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